|
Beta-Agonist Lung injury TrIal-2 (BALTI-2): a multicentre, randomised, double-blind, placebo-controlled trial and economic evaluation of intravenous infusion of salbutamol versus placebo in patients with acute respiratory distress syndrome |
Gates S, Perkins G, Lamb S, Kelly C, Thickett D, Young J, McAuley D, Snaith C, McCabe C, Hulme C, Gao Smith F |
|
|
Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Gates S, Perkins G, Lamb S, Kelly C, Thickett D, Young J, McAuley D, Snaith C, McCabe C, Hulme C, Gao Smith F. Beta-Agonist Lung injury TrIal-2 (BALTI-2): a multicentre, randomised, double-blind, placebo-controlled trial and economic evaluation of intravenous infusion of salbutamol versus placebo in patients with acute respiratory distress syndrome. Health Technology Assessment 2013; 17(38): 1-87 Authors' objectives To evaluate whether or not, in patients with ARDS, an i.v. infusion of salbutamol given at 15 g/kg ideal body weight (IBW)/hour for up to 7 days, compared with a placebo (0.9% sodium chloride) infusion, reduces 28-day all-cause mortality and other clinical outcomes. To evaluate salbutamol's clinical effectiveness and its cost-effectiveness in subgroups of patients. Authors' conclusions Treatment with i.v. salbutamol early in the course of ARDS was poorly tolerated, is unlikely to be beneficial and could worsen outcomes. Further trials of -agonists in patients with ARDS are unlikely to be conducted. Some questions remain, such as whether or not there may be benefit at a different dose or in specific populations, but any studies investigating these would require a very strong rationale. Indexing Status Subject indexing assigned by CRD MeSH Adrenergic beta-2 Receptor Agonists; Albuterol; Cost-Benefit Analysis; Humans; Lung Injury; Respiratory Distress Syndrome, Adult Language Published English Country of organisation England English summary An English language summary is available. Address for correspondence NETSCC, Health Technology Assessment, Alpha House, University of Southampton Science Park, Southampton, SO16 7NS UK Tel: +44 23 8059 5586 Email: hta@hta.ac.uk AccessionNumber 32013000714 Date abstract record published 14/10/2013 |
|
|
|